All companies › AGMB

AGMB · AgomAb Therapeutics NV

Everything on this page is public record — SEC Form 4 filings and congressional disclosures — alongside any INSIDER SCANNER research case for this company.

Open-market buys6
Open-market sells0
Total purchased$217,440
Unique insiders buying3
Most senior buyerCEO
Avg price paid$8.70
Research cases0
Last filing2026-10-08

Average price paid is weighted by shares, so a large purchase counts for more than a small one. It is what insiders reported paying, not a target or a fair value.

Insider flow: Buying only — a count of disclosed transactions, not a rating or a recommendation.

Insider transaction timeline

Every reported transaction, positioned by trade date. Purchases sit above the axis, sales below; circle area is proportional to dollar value. No share-price line is drawn — this feed carries transaction prices only, and a price history inferred from them would imply market data the filings do not contain.

Open-market purchase Open-market sale
2026-10-06 — Kemula Pierre Thadee Victor · bought 3,000 @ $8.67 2026-10-06 — Kemula Pierre Thadee Victor · bought 5,000 @ $8.57 2026-10-06 — Kemula Pierre Thadee Victor · bought 2,000 @ $8.54 2026-10-06 — Knotnerus Tim Jasper · bought 5,000 @ $8.70 2026-10-06 — Epstein David R · bought 5,000 @ $8.70 2026-10-08 — Epstein David R · bought 5,000 @ $8.90
2026-10-062026-10-08

Insider cost basis

Share-weighted average price across 6 reported purchases, with the full range of prices paid. Purchases only — averaging a sale into an "insider cost" would describe a price nobody paid.

$8.54 $8.90
$8.70 weighted average insider purchase price

Insider participation

One row per insider, one cell per reported transaction, shaded by value. Repeat buying and activity clustered in time are visible at a glance.

Kemula Pierre Thadee Victor Chief Financial Officer
Epstein David R Director
Knotnerus Tim Jasper Chief Executive Officer, Director
Included with a free account

The analysis built on top of these filings

The filings above are public record and stay public here. What an account adds for $AGMB is the reading of them — and for this company, that is what the list below says it is, no more.

  • Insider cost basisShare-weighted average price paid across the 6 reported purchases, with the full range, against the current price.
  • Insider participationWho bought, how often, and how the buying is distributed across the people filing — one person repeating is not several agreeing.
  • Transaction timelineThe [{'transaction_date': '2026-10-08', 'insider_name': 'Epstein David R', 'insider_title': 'Director', 'transaction_type': 'Open-market buy', 'shares': 5000.0, 'price': 8.9, 'value': 44500.0, 'is_buy': True}, {'transaction_date': '2026-10-06', 'insider_name': 'Kemula Pierre Thadee Victor', 'insider_title': 'Chief Financial Officer', 'transaction_type': 'Open-market buy', 'shares': 3000.0, 'price': 8.67, 'value': 26010.0, 'is_buy': True}, {'transaction_date': '2026-10-06', 'insider_name': 'Kemula Pierre Thadee Victor', 'insider_title': 'Chief Financial Officer', 'transaction_type': 'Open-market buy', 'shares': 5000.0, 'price': 8.57, 'value': 42850.0, 'is_buy': True}, {'transaction_date': '2026-10-06', 'insider_name': 'Kemula Pierre Thadee Victor', 'insider_title': 'Chief Financial Officer', 'transaction_type': 'Open-market buy', 'shares': 2000.0, 'price': 8.54, 'value': 17080.0, 'is_buy': True}, {'transaction_date': '2026-10-06', 'insider_name': 'Knotnerus Tim Jasper', 'insider_title': 'Chief Executive Officer, Director', 'transaction_type': 'Open-market buy', 'shares': 5000.0, 'price': 8.7, 'value': 43500.0, 'is_buy': True}, {'transaction_date': '2026-10-06', 'insider_name': 'Epstein David R', 'insider_title': 'Director', 'transaction_type': 'Open-market buy', 'shares': 5000.0, 'price': 8.7, 'value': 43500.0, 'is_buy': True}] reported transactions plotted over the window rather than listed, so concentration is visible.

Not available for AGMB today: no research case — nothing here has cleared the scoring threshold. Both appear on this page on their own if that changes.

A free account opens all of it.

Not financial advice. This page reports public filings and past research output. It is not a recommendation to buy or sell, and no price target here is a prediction. Trade at your own risk.